<DOC>
	<DOCNO>NCT00002041</DOCNO>
	<brief_summary>To determine appropriate duration amphotericin B therapy Candida esophagitis . To compare effectiveness two different amphotericin B dose treatment biopsy-proven Candida esophagitis . To determine low-dose amphotericin B less toxic standard dose therapy limited treatment period . To evaluate pharmacokinetic pharmacodynamic parameter two different dose regimen .</brief_summary>
	<brief_title>Evaluation Amphotericin B Treatment Biopsy Proven Candida Esophagitis Immunocompromised Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition : Patients histological clinical ( skin rash , cotton wool exudate , Candida endophthalmitis , etc . ) evidence disseminate candidiasis exclude . Concurrent Medication : Excluded : Systemic administration amphotericin B proven suspect systemic fungal infection . Patients follow exclude : Documented Candida fungemia . Histological clinical ( skin rash , cotton wool exudate , Candida endophthalmitis , etc . ) evidence disseminate candidiasis . Systemic administration amphotericin B proven suspect systemic fungal infection . Patient refusal enter study . Patient must immunosuppressed host , biopsyproven Candida esophagitis . Patients polymicrobial esophagitis include long Candida esophagitis document esophageal biopsy . Informed consent must sign obtain .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Esophagitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
	<keyword>Candidiasis , Oral</keyword>
</DOC>